News | Computed Tomography (CT) | June 17, 2019

International Working Group Releases New Multiple Myeloma Imaging Guidelines

Recommendations guide optimal use of new imaging techniques

International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

June 17, 2019 — An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for imaging techniques to help diagnose multiple myeloma and other plasma-cell disorders.

Just as newer drugs have significantly improved outcomes for patients with multiple myeloma in the past decade, newer imaging techniques are upgrading detection of the disease, leading to earlier treatment. But standards to help guide clinicians on the optimal use of advanced imaging have lagged behind until now.

Jens Hillengass, M.D., chief of myeloma at Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., led the IMWG effort to compile new recommendations for imaging techniques that offer more sensitive and accurate diagnosis and monitoring for patients with multiple myeloma and other plasma-cell disorders. Multiple myeloma — the second most common type of blood cancer — occurs when white blood cells known as plasma cells multiply out of control.

“Use of newer imaging techniques is changing the whole landscape, from diagnosis to treatment to supportive care to survivorship, and all those things are coming into this direction of research in multiple myeloma right now,” said Hillengass.

Hillengass and a team of two experts developed the guidelines, which were then reviewed by the entire working group. Their findings have been newly published in the journal The Lancet Oncology.1

The guidelines are based in part on an examination of results of computed tomography (CT) and X-ray imaging from several countries. The team found that using only conventional X-ray misses 25 percent of instances where patients have bone destruction already and need treatment.

“There has to be destruction of 30-50 percent of the bone, sometimes up to 70 percent, before you see anything on X-ray,” said Hillengass, who is first author on the new guidelines. “More sophisticated imaging is necessary not only in the beginning to assess the disease but also to assess the response and to see what is left after our standard treatment. Myeloma is a disease that can cause focal and diffuse destruction of the bone, and to see that, you need sharp imaging.”

The major change in the new imaging guidelines is that whole-body low-dose CT replaces conventional skeletal survey as the standard imaging technique recommended for assessing bone destruction. The IMWG team recommends that this more sophisticated technique and others, including positron emission tomography-CT (PET-CT) and magnetic resonance imaging (MRI) be introduced generally into clinical practices.

These practices are already employed in the clinical care of myeloma patients at Roswell Park, and a team at the cancer center is conducting a clinical trial to explore what CT-guided biopsies of focal lesions may reveal about the spatial and temporal heterogeneity of this disease.

Hillengass hopes that broader application of these newer techniques will lead to more refined imaging, more accurate diagnoses, earlier treatments and more patients living longer due to lasting remissions.

“There’s a lot of research underway now exploring whether incorporating more specific traces or dyes into various imaging techniques will be beneficial, and also to figure out how we can assess minimal residual disease, or very low tumor burdens after treatment,” he noted. “Therefore, we need much higher sensitivity and also functional information that cutting-edge imagery can provide. There are important questions still to be asked as these technologies evolve.”

The International Myeloma Foundation formed the IMWG in 2001 to encourage dialogue and collaboration among the world’s leading myeloma experts. The group includes 243 members from 39 countries who collaboratively conduct research to improve outcomes of the disease and provide scientifically valid consensus opinions regarding its diagnosis and treatment.

The paper, “International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders, is available online.

For more information: www.sciencedirect.com

Reference

1. Hillengass J., Usmani S., Rajkumar S.V., et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. The Lancet Oncology, published online May 29, 2019. https://doi.org/10.1016/S1470-2045(19)30309-2

Related Content

Numerical simulation with a heterogeneous mouse

Numerical simulation with a heterogeneous mouse. (a) The geometry of the mouse with major organs near the source, and (b) the surface fluence computed with TIM-OS. Image courtesy of Rensselaer Polytechnic Institute.

News | Oncology Diagnostics | September 20, 2019
If researchers could observe drug delivery and its effect on cancer cells in real time, they would be able to tailor...
Screening Mammography Could Benefit Men at High Risk of Breast Cancer
News | Mammography | September 18, 2019
Selective mammography screening can provide potentially lifesaving early detection of breast cancer in men who are at...
The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning

The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning. Image courtesy of Siemens Healthineers.

News | Computed Tomography (CT) | September 15, 2019
Siemens Healthineers debuted two computed tomography (CT) systems dedicated to radiation therapy (RT) planning at the...
Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019
News | Radiation Oncology | September 13, 2019
Philips will showcase its integrated radiation oncology portfolio at the American Society of Radiation Oncology (ASTRO...
RefleXion Highlights Novel Approach to Radiotherapy at ASTRO 2019

The RefleXion X1 Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. Image courtesy of Reflexion Medical.

News | Radiation Therapy | September 12, 2019
Therapeutic oncology company RefleXion Medical announced it will showcase the RefleXion X1 Machine at the American...
Richardson Healthcare Receives CE Mark Approval for ALTA750 Canon/Toshiba CT Replacement Tube
News | Computed Tomography (CT) | September 11, 2019
Richardson Healthcare, a Division of Richardson Electronics Ltd., announced it has received CE Mark approval for the...
Bayer Introduces Medrad Stellant Flex CT Injection System
Technology | Contrast Media Injectors | September 11, 2019
Bayer announced the introduction of the Medrad Stellant Flex computed tomography (CT) injection system. Stellant Flex...
iCAD's ProFound AI Wins Best New Radiology Solution in 2019 MedTech Breakthrough Awards
News | Computer-Aided Detection Software | September 09, 2019
iCAD Inc. announced MedTech Breakthrough, an independent organization that recognizes the top companies and solutions...
Imaging Biometrics and Medical College of Wisconsin Awarded NIH Grant
News | Neuro Imaging | September 09, 2019
Imaging Biometrics LLC (IB), in collaboration with the Medical College of Wisconsin (MCW), has received a $2.75 million...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along